{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:23:40Z","timestamp":1775244220673,"version":"3.50.1"},"reference-count":106,"publisher":"European Respiratory Society (ERS)","issue":"129","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2013,5,3]]},"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is a progressive disease characterised by remodelling of small pulmonary arteries leading to an increased pulmonary vascular resistance, right ventricular failure and death. Available treatments try to re-establish the equilibrium on three signalling pathways: the prostacyclin, the endothelin (ET)-1 and the nitric oxide. Prostanoids, such as epoprostenol or treprostinil have a vasodilator, antiproliferative and immunomodulatory effect and, despite the administration inconveniences, represent established therapies for severe cases of PAH. Recently oral prostacyclin receptor agonists have shown encouraging results. Many clinical studies targeting the vasoconstrictor ET-1 pathway with receptor antagonists like bosentan and ambrisentan have shown strong results, even more optimism coming from macitentan, the newest drug. Sildenafil and tadalafil, two phosphodiesterase type-5 inhibitors, have shown improved exercise capacity by increasing the nitric oxide level. Riociguat, acting on the same nitric oxide pathway, as a guanylatecyclase activator, has shown promising results in clinical trials and will be available soon. Long-awaited results for tyrosin-kinase inhibitor, imatinib, as an antiproliferative therapy in PAH have been disappointing, due to severe adverse events. In conclusion, although it remains a disease with severe prognosis, the past 20 years have represented a huge progress in terms of treatments for PAH with interesting opportunities for the future.<\/jats:p>","DOI":"10.1183\/09059180.00001713","type":"journal-article","created":{"date-parts":[[2013,8,31]],"date-time":"2013-08-31T01:29:40Z","timestamp":1377912580000},"page":"217-226","source":"Crossref","is-referenced-by-count":68,"title":["Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?"],"prefix":"10.1183","volume":"22","author":[{"given":"Andrei","family":"Seferian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2013,8,30]]},"reference":[{"key":"2025042406001608000_22.129.217.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701093360207"},{"key":"2025042406001608000_22.129.217.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.012"},{"key":"2025042406001608000_22.129.217.3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.22.2781"},{"key":"2025042406001608000_22.129.217.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.107821"},{"key":"2025042406001608000_22.129.217.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2012.07.033"},{"key":"2025042406001608000_22.129.217.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00320-4"},{"key":"2025042406001608000_22.129.217.7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"2025042406001608000_22.129.217.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"2025042406001608000_22.129.217.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00139009"},{"key":"2025042406001608000_22.129.217.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2010.02.039"},{"key":"2025042406001608000_22.129.217.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"2025042406001608000_22.129.217.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207093270202"},{"key":"2025042406001608000_22.129.217.13","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.6.9804054"},{"key":"2025042406001608000_22.129.217.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-5884(03)00385-X"},{"key":"2025042406001608000_22.129.217.15","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.25.3130"},{"key":"2025042406001608000_22.129.217.16","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000121568.40692.97"},{"key":"2025042406001608000_22.129.217.17","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.2.249"},{"key":"2025042406001608000_22.129.217.18","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00005909"},{"key":"2025042406001608000_22.129.217.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-7-485"},{"key":"2025042406001608000_22.129.217.20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-6-199409150-00003"},{"key":"2025042406001608000_22.129.217.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2025042406001608000_22.129.217.22","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"2025042406001608000_22.129.217.23","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200408000-00010"},{"key":"2025042406001608000_22.129.217.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200505-766OC"},{"key":"2025042406001608000_22.129.217.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"2025042406001608000_22.129.217.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2212"},{"key":"2025042406001608000_22.129.217.27","unstructured":"PR Newswire. FREEDOM-M trial of oral treprostinil in pulmonary arterial hypertension meets primary endpoint. http:\/\/www.prnewswire.com\/news-releases\/freedom-m-trial-of-oral-treprostinil-in-pulmonary-arterial-hypertension-meets-primary-endpoint-123212773.html Date last accessed: January 2013. Date last updated: June 6, 2011."},{"key":"2025042406001608000_22.129.217.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"2025042406001608000_22.129.217.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi283"},{"key":"2025042406001608000_22.129.217.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00130408"},{"key":"2025042406001608000_22.129.217.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01786-2"},{"key":"2025042406001608000_22.129.217.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"2025042406001608000_22.129.217.33","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.124248"},{"key":"2025042406001608000_22.129.217.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137511"},{"key":"2025042406001608000_22.129.217.35","doi-asserted-by":"publisher","DOI":"10.4103\/0971-9784.38443"},{"key":"2025042406001608000_22.129.217.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00158.x"},{"key":"2025042406001608000_22.129.217.37","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000158262.11935.d0"},{"key":"2025042406001608000_22.129.217.38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116338"},{"key":"2025042406001608000_22.129.217.39","doi-asserted-by":"publisher","DOI":"10.2217\/14796678.1.4.425"},{"issue":"Suppl. 3","key":"2025042406001608000_22.129.217.40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2362.2006.01691.x","article-title":"Dual ET(A)\/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension","volume":"36","author":"Opitz","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"2025042406001608000_22.129.217.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"2025042406001608000_22.129.217.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"2025042406001608000_22.129.217.43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.630715"},{"key":"2025042406001608000_22.129.217.44","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-445OC"},{"key":"2025042406001608000_22.129.217.45","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00080804"},{"key":"2025042406001608000_22.129.217.46","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1028"},{"key":"2025042406001608000_22.129.217.47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"2025042406001608000_22.129.217.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.033"},{"key":"2025042406001608000_22.129.217.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2011.00279.x"},{"key":"2025042406001608000_22.129.217.50","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142976"},{"key":"2025042406001608000_22.129.217.51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047662"},{"key":"2025042406001608000_22.129.217.52","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1043-2"},{"key":"2025042406001608000_22.129.217.53","unstructured":"Actelion. Macitentan. http:\/\/www1.actelion.com\/sites\/en\/scientists\/development-pipeline\/phase-3\/macitentan.page Date last accessed January 2013. Date Last updated: January 2013."},{"key":"2025042406001608000_22.129.217.54","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1456207"},{"key":"2025042406001608000_22.129.217.55","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200307-957OC"},{"key":"2025042406001608000_22.129.217.56","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00058409"},{"key":"2025042406001608000_22.129.217.57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.503540"},{"key":"2025042406001608000_22.129.217.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"2025042406001608000_22.129.217.59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"2025042406001608000_22.129.217.60","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.564159"},{"key":"2025042406001608000_22.129.217.61","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00011112"},{"key":"2025042406001608000_22.129.217.62","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0969"},{"key":"2025042406001608000_22.129.217.63","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1462799"},{"key":"2025042406001608000_22.129.217.64","unstructured":"Wayne NJ . Bayer's investigational riociguat meets primary endpoint in phase III study in patients with pulmonary arterial huypertension (PAH). www.prnewswire.com\/news-releases\/bayers-investigational-riociguat-meets-primary-endpoint-in-phase-iii-study-in-patients-with-pulmonary-arterial-hypertension-pah-175181281.html Date last accessed: January 2013. Date last updated: October 22, 2012."},{"key":"2025042406001608000_22.129.217.65","unstructured":"Bayer's investigational riociguat meets primary endpoint in phase III study of patients with chronic thromboembolic pulmonary hypertension (CTEPH). www.prnewswire.com\/news-releases\/bayers-investigational-riociguat-meets-primary-endpoint-in-phase-iii-study-of-patients-with-chronic-thromboembolic-pulmonary-hypertension-cteph-175479511.html Date last accessed: January 2013. Date last updated: October 23, 2012."},{"key":"2025042406001608000_22.129.217.66","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.674002"},{"key":"2025042406001608000_22.129.217.67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.488486"},{"key":"2025042406001608000_22.129.217.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.017"},{"key":"2025042406001608000_22.129.217.69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.24.3160"},{"key":"2025042406001608000_22.129.217.70","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.11030554"},{"key":"2025042406001608000_22.129.217.71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26593"},{"key":"2025042406001608000_22.129.217.72","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2025042406001608000_22.129.217.73","unstructured":"Hoeper M Barst RJ Gali\u00e9 N . Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES). Eur Respir J; 2011; Suppl. 55, A413."},{"key":"2025042406001608000_22.129.217.74","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0371OC"},{"key":"2025042406001608000_22.129.217.75","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1103-0"},{"key":"2025042406001608000_22.129.217.76","doi-asserted-by":"publisher","DOI":"10.1080\/02841860903229124"},{"key":"2025042406001608000_22.129.217.77","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2106"},{"key":"2025042406001608000_22.129.217.78","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"2025042406001608000_22.129.217.79","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80156-9"},{"key":"2025042406001608000_22.129.217.80","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.241"},{"key":"2025042406001608000_22.129.217.81","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00126010"},{"key":"2025042406001608000_22.129.217.82","first-page":"A2496","article-title":"Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study","volume":"185","author":"Ghofrani","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042406001608000_22.129.217.83","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317500"},{"key":"2025042406001608000_22.129.217.84","first-page":"L1047","article-title":"VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells","volume":"268","author":"Maruno","year":"1995","journal-title":"Am J Physiol"},{"key":"2025042406001608000_22.129.217.85","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(84)90228-6"},{"key":"2025042406001608000_22.129.217.86","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00050008"},{"key":"2025042406001608000_22.129.217.87","first-page":"A2516","article-title":"Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH)","volume":"181","author":"Gali\u00e8","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2025042406001608000_22.129.217.88","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-637OC"},{"key":"2025042406001608000_22.129.217.89","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.90251.2008"},{"key":"2025042406001608000_22.129.217.90","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-009-1176-8"},{"key":"2025042406001608000_22.129.217.91","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.029470"},{"key":"2025042406001608000_22.129.217.92","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1699OC"},{"key":"2025042406001608000_22.129.217.93","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.015693"},{"issue":"Suppl. 2","key":"2025042406001608000_22.129.217.94","first-page":"H622","article-title":"Adrenomedullin activity in chronically hypoxic rat lungs","volume":"271","author":"Zhao","year":"1996","journal-title":"Am J Physiol"},{"key":"2025042406001608000_22.129.217.95","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000109493.05849.14"},{"key":"2025042406001608000_22.129.217.96","doi-asserted-by":"publisher","DOI":"10.1038\/nature05919"},{"key":"2025042406001608000_22.129.217.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.07.016"},{"key":"2025042406001608000_22.129.217.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2010.08.009"},{"key":"2025042406001608000_22.129.217.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2006.02.033"},{"key":"2025042406001608000_22.129.217.100","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00047.2008"},{"key":"2025042406001608000_22.129.217.101","doi-asserted-by":"publisher","DOI":"10.1038\/79226"},{"key":"2025042406001608000_22.129.217.102","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000012754.72951.3D"},{"key":"2025042406001608000_22.129.217.103","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00187310"},{"key":"2025042406001608000_22.129.217.104","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09020356"},{"key":"2025042406001608000_22.129.217.105","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.618397"},{"key":"2025042406001608000_22.129.217.106","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000164074.64137.f1"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09059180.00001713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:00:41Z","timestamp":1745499641000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09059180.00001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,30]]},"references-count":106,"journal-issue":{"issue":"129","published-online":{"date-parts":[[2013,8,30]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1183\/09059180.00001713"],"URL":"https:\/\/doi.org\/10.1183\/09059180.00001713","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,30]]}}}